- Home
- NBRG vs ANVS Comparison
NBRG vs ANVS Comparison
Compare NBRG & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$1.92
Company Overview
Basic Information| Metric | NBRG | ANVS |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.3M | 69.1M |
| IPO Year | 2026 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NBRG | ANVS |
|---|---|---|
| Price | $9.97 | $1.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 4.6K | ★ 767.8K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.59 | $1.54 |
| 52 Week High | $10.00 | $5.50 |
Technical Indicators
Market Signals| Indicator | NBRG | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 60.91 |
| Support Level | $9.96 | $1.73 |
| Resistance Level | $9.99 | $2.07 |
| Average True Range (ATR) | 0.00 | 0.10 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 25.00 | 92.72 |
Price Performance
Historical Comparison NBRG
ANVS
About NBRG Newbridge Acquisition Limited Class A Ordinary Share
Newbridge Acquisition Ltd is a blank check company.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.